6.1
The Committee recognised that the available clinical data on the effectiveness of EXOGEN for treating long bone fractures with non-union show high rates of fracture healing and it judged them sufficient to support the efficacy and utility of EXOGEN treatment. Despite the absence of direct evidence on avoiding surgery, the Committee considered that the assumptions in the cost model were plausible and that EXOGEN is cost saving compared with current management for the treatment of non-union. Overall, therefore, the case for adoption of EXOGEN in the treatment of long bone fractures with non-union was found to be supported by the evidence.